Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
Top Cited Papers
- 12 March 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 136 (1), 116-124.e7
- https://doi.org/10.1016/j.jaci.2015.01.018
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Pfizer
- Eli Lilly and Company
This publication has 24 references indexed in Scilit:
- Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular EventsAmerican Journal Of Medicine, 2011
- PsoriasisThe New England Journal of Medicine, 2009
- Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathwaysNature Genetics, 2009
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic CellsJournal of Investigative Dermatology, 2009
- The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene listsGenome Biology, 2007
- A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk GenesAmerican Journal of Human Genetics, 2007
- British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005British Journal of Dermatology, 2005
- Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global AssessmentJournal of the American Academy of Dermatology, 2004
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Oral Treatment of Pustulosis Palmo-Plantaris with a New Retinoid, Ro 10-9359Dermatology, 1979